

\n\n\n \n \n \n \n \n \n \n \n \n \n

Medical Necessity Letter

\n

To, Sophia Chen

\n

09/20/2010

\n

Diagnosis

\n

J45.909 (Unspecified asthma, uncomplicated, persistent)

\n

Proposed Treatment

\n

Biologic therapy (e.g., Omalizumab)

\n

Detailed Explanation

\n

Sophia Chen has severe persistent allergic asthma, characterized by frequent exacerbations (requiring oral corticosteroids >2 times in the last year), persistent symptoms (daily wheezing, cough, shortness of breath), and significant impairment in school attendance and physical activity, despite optimal adherence to high-dose inhaled corticosteroids and long-acting beta-agonists. Her IgE levels are elevated, consistent with allergic asthma. Risks of not receiving this advanced therapy include continued frequent severe asthma attacks, potential for irreversible airway remodeling, chronic lung damage, and a diminished quality of life. Less intensive treatments have failed to control her disease adequately, and increasing the dose of current medications or adding more conventional therapies would not address the underlying allergic inflammatory pathway driving her severe asthma. Biologic therapy, specifically Omalizumab, is medically necessary as it targets IgE, reducing allergic inflammation and thereby decreasing exacerbation frequency and improving asthma control in patients with severe allergic asthma refractory to conventional therapy.

\n

Doctor's Signature

\n

\n\n